Clinical Trials
34 trialsNCT02972840 2026-06-01
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT04224493 2026-06-01
SYMPHONY-1
Ipsen
Phase 3 Active not recruiting
NCT02048813 2026-05-29
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02003222 2026-05-28
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04002297 2026-05-18
MANGROVE
BeOne Medicines
Phase 3 Active not recruiting
NCT02970318 2026-05-11
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Phase 3 Active not recruiting
NCT06230224 2026-05-11
OLYMPIA-4
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT05171647 2026-05-07
SUNMO
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03267433 2026-05-05
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT04712097 2026-05-05
Celestimo
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT01886872 2026-05-04
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04384484 2026-04-28
LOTIS 5
ADC Therapeutics S.A.
Phase 3 Active not recruiting
NCT04666038 2026-04-24
BRUIN CLL-321
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04404283 2026-04-20
ECHELON-3
Seagen Inc.
Phase 3 Active not recruiting
NCT05888493 2026-04-17
LEDA
Novartis
Phase 3 Active not recruiting
NCT06508658 2026-04-08
EPCORE DLBCL-4
Genmab
Phase 3 Active not recruiting
NCT04824092 2026-04-01
frontMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT04529772 2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3 Active not recruiting
NCT05624554 2026-03-16
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03336333 2026-03-09
SEQUOIA
BeOne Medicines
Phase 3 Active not recruiting
NCT04075292 2026-03-05
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
AstraZeneca
Phase 3 Active not recruiting
NCT06356129 2026-02-12
GOLSEEK-1
Celgene
Phase 3 Active not recruiting
NCT06097364 2026-02-06
OLYMPIA-2
Regeneron Pharmaceuticals
Phase 3 Active not recruiting
NCT04965493 2026-01-29
BRUIN CLL-322
Eli Lilly and Company
Phase 3 Active not recruiting
NCT05023980 2026-01-22
BRUIN CLL-313
Eli Lilly and Company
Phase 3 Active not recruiting
NCT04680052 2025-12-22
InMIND
Incyte Corporation
Phase 3 Active not recruiting
NCT05457556 2025-12-22
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
Children's Oncology Group
Phase 3 Active not recruiting
NCT02390869 2025-12-02
FIL_RENOIR12
Fondazione Italiana Linfomi - ETS
Phase 3 Active not recruiting
NCT05371093 2025-10-15
ZUMA-22
Gilead Sciences
Phase 3 Active not recruiting
NCT04833114 2025-09-30
Pola-R-ICE
GWT-TUD GmbH
Phase 3 Active not recruiting
NCT05409066 2025-07-28
EPCORE FL-1
Genmab
Phase 3 Active not recruiting
NCT04212013 2025-07-23
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 3 Active not recruiting
NCT05578976 2025-01-23
EPCORE DLBCL-2
Genmab
Phase 3 Active not recruiting
NCT00877214 2024-08-22
MAINTAIN
University of Giessen
Phase 3 Active not recruiting